Anthrax and plague vaccine-oral - AVANT
Latest Information Update: 03 May 2007
At a glance
- Originator AVANT Immunotherapeutics
- Developer DynPort Vaccine Company LLC
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anthrax; Yersinia infections
Most Recent Events
- 03 May 2007 Discontinued - Preclinical for Anthrax in USA (PO)
- 03 May 2007 Discontinued - Preclinical for Yersinia infections in USA (PO)
- 23 Aug 2004 DynPort Vaccine Company LLC has been acquired by Computer Sciences Corporation